
Tango Therapeutics, Inc.: shareholders and insiders
Price
$22.71
November 19, 2026Market cap $3.8B
What Ploutos Investor adds for Tango Therapeutics
Part of Ploutos Investor, €9.99 a month
- The full history: 6 fiscal years, from 2020
- The estimated fair value, with its range and its certainty
- The full analysis, 18 a month
- More questions to the chat on its filings
- Excel with every year
- An email when it reports, changes its dividend or an officer buys
Sign in with a free account to see the last 5 fiscal years.
Insiders and their shares
Purchases and sales by officers and directors from Nov 20, 2025 to Nov 19, 2026, from their own Form 4 filings.
Bought on the market
–
nobody
Sold on the market
$8.2M
5 people
From Nov 20, 2025 to Nov 20, 2026, the days the chart shows. Change its range and the figures follow.
How the sales were made, as a share of their value
- Under a set plan91%
- The rest9%
By year
Insiders' open-market purchases (up) and sales (down), by value, since Nov 20, 2025, on a log scale: each gridline is ten times the last. From the SEC's quarterly data sets of Form 4 filings.
2026·no buys·sold $8.2M by 5 people
- 2025: no buys, no sales
- 2026: no buys, sold $8.2M by 5 people
- Nov 17, 2026John B KetchumDirectorKind10b5-1
- Nov 11, 2026Adam CrystalPresident, R&DKind10b5-1
- Nov 11, 2026Adam CrystalPresident, R&DKind10b5-1
- Nov 2, 2026Adam CrystalPresident, R&DKind10b5-1
- Nov 2, 2026Adam CrystalPresident, R&DKind10b5-1
- Nov 2, 2026Adam CrystalPresident, R&DKind10b5-1
- Nov 2, 2026Jessica NewcombPrincipal Accounting OfficerKind10b5-1
- Nov 2, 2026Jessica NewcombPrincipal Accounting OfficerKind10b5-1
- Oct 1, 2026Adam CrystalPresident, R&DKind10b5-1
- Oct 1, 2026Adam CrystalPresident, R&DKind10b5-1
- Oct 1, 2026Adam CrystalPresident, R&DKind10b5-1
- Sep 22, 2026Jessica NewcombPrincipal Accounting OfficerKind10b5-1
- Sep 22, 2026Jessica NewcombPrincipal Accounting OfficerKind10b5-1
- Sep 22, 2026Jessica NewcombPrincipal Accounting OfficerKind10b5-1
- Sep 1, 2026Adam CrystalPresident, R&DKind10b5-1
- Sep 1, 2026Adam CrystalPresident, R&DKind10b5-1
- Aug 3, 2026Adam CrystalPresident, R&DKind10b5-1
- Aug 3, 2026Adam CrystalPresident, R&DKind10b5-1
- Aug 3, 2026Adam CrystalPresident, R&DKind10b5-1
- Jul 1, 2026Adam CrystalPresident, R&DKind10b5-1
- Jul 1, 2026Adam CrystalPresident, R&DKind10b5-1
- Jul 1, 2026Adam CrystalPresident, R&DKind10b5-1
- Jun 19, 2026Robert AzelbyDirectorKind
- Jun 5, 2026John B KetchumDirectorKind
- Jun 5, 2026Lesley Ann CalhounDirectorKind
| Date | Person | Kind | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Nov 17, 2026 | John B KetchumDirector | 10b5-1 | 3,333 | $24.08 | $80.3K | Form 4 |
| Nov 11, 2026 | Adam CrystalPresident, R&D | 10b5-1 | 5,000 | $2.91 | $14.6K | Form 4 |
| Nov 11, 2026 | Adam CrystalPresident, R&D | 10b5-1 | 5,000 | $25.00 | $125.0K | Form 4 |
| Nov 2, 2026 | Adam CrystalPresident, R&D | 10b5-1 | 5,000 | $2.91 | $14.6K | Form 4 |
| Nov 2, 2026 | Adam CrystalPresident, R&D | 10b5-1 | 3,900 | $22.26 | $86.8K | Form 4 |
| Nov 2, 2026 | Adam CrystalPresident, R&D | 10b5-1 | 1,100 | $22.99 | $25.3K | Form 4 |
| Nov 2, 2026 | Jessica NewcombPrincipal Accounting Officer | 10b5-1 | 5,571 | $22.28 | $124.1K | Form 4 |
| Nov 2, 2026 | Jessica NewcombPrincipal Accounting Officer | 10b5-1 | 1,460 | $22.98 | $33.6K | Form 4 |
| Oct 1, 2026 | Adam CrystalPresident, R&D | 10b5-1 | 27.0K | $5.20 | $140.4K | Form 4 |
| Oct 1, 2026 | Adam CrystalPresident, R&D | 10b5-1 | 26.4K | $24.45 | $645.6K | Form 4 |
| Oct 1, 2026 | Adam CrystalPresident, R&D | 10b5-1 | 600 | $25.32 | $15.2K | Form 4 |
| Sep 22, 2026 | Jessica NewcombPrincipal Accounting Officer | 10b5-1 | 700 | $22.80 | $16.0K | Form 4 |
| Sep 22, 2026 | Jessica NewcombPrincipal Accounting Officer | 10b5-1 | 5,100 | $23.97 | $122.2K | Form 4 |
| Sep 22, 2026 | Jessica NewcombPrincipal Accounting Officer | 10b5-1 | 2,400 | $25.17 | $60.4K | Form 4 |
| Sep 1, 2026 | Adam CrystalPresident, R&D | 10b5-1 | 27.0K | $5.20 | $140.4K | Form 4 |
| Sep 1, 2026 | Adam CrystalPresident, R&D | 10b5-1 | 27.0K | $22.37 | $603.9K | Form 4 |
| Aug 3, 2026 | Adam CrystalPresident, R&D | 10b5-1 | 27.0K | $5.20 | $140.4K | Form 4 |
| Aug 3, 2026 | Adam CrystalPresident, R&D | 10b5-1 | 5,267 | $26.79 | $141.1K | Form 4 |
| Aug 3, 2026 | Adam CrystalPresident, R&D | 10b5-1 | 21.7K | $27.35 | $594.4K | Form 4 |
| Jul 1, 2026 | Adam CrystalPresident, R&D | 10b5-1 | 27.0K | $5.20 | $140.4K | Form 4 |
| Jul 1, 2026 | Adam CrystalPresident, R&D | 10b5-1 | 19.6K | $29.34 | $576.0K | Form 4 |
| Jul 1, 2026 | Adam CrystalPresident, R&D | 10b5-1 | 7,371 | $30.25 | $222.9K | Form 4 |
| Jun 19, 2026 | Robert AzelbyDirector | 5,740 | – | – | Form 4 | |
| Jun 5, 2026 | John B KetchumDirector | 4,000 | – | – | Form 4 | |
| Jun 5, 2026 | Lesley Ann CalhounDirector | 4,000 | – | – | Form 4 |
From the Form 4s insiders file with the SEC within two business days of each trade. Before Jun 3, 2026 the table lists open-market purchases and sales only (no grants, option exercises or tax withholding), from the SEC's quarterly data sets. The 10b5-1 mark comes from the form's own box (since April 2023) or from a footnote of the filing that names the plan, where there is one.
Insiders and their shares
Every buy and sale by TNGX's officers and directors from 2020 up to November 19, 2025, 6 more calendar years
Part of Ploutos Investor, €9.99 a month
Sign in with a free account to see the last 3 years.
and 1 more, back to 2020
Major holders (over 5%)
Whoever comes to own more than 5% of a class of shares reports it to the SEC on Schedule 13D or 13G. Here is each holder's latest filing.
- FMRwith 1 more personShare of class15.0%
- BCTG Holdings, LLCwith 3 more personsShare of class10.0%
- Farallon Capital Management, L.L.C.with 28 more personsShare of class9.80%
- RTW Investments, LPwith 1 more personShare of class9.30%
- TCG Crossover GP II, LLCwith 2 more personsShare of class7.00%
- BlackRock, Inc.Share of class6.30%
- The Goldman Sachs Groupwith 1 more personShare of class6.00%
| Holder | Kind of stake | Share of class | Shares | Filed | Filing |
|---|---|---|---|---|---|
| FMRwith 1 more person | 15.0% | 25.29M | Nov 6, 20263 filings since Dec 6, 2024 | 13G/A | |
| BCTG Holdings, LLCwith 3 more persons | 10.0% | 10.74M | Jan 2, 2025 | 13D/A | |
| Farallon Capital Management, L.L.C.with 28 more persons | 9.80% | 16.27M | Aug 14, 20266 filings since Jun 13, 2025 | 13G/A | |
| RTW Investments, LPwith 1 more person | 9.30% | 13.30M | May 15, 2026 | 13G | |
| TCG Crossover GP II, LLCwith 2 more persons | 7.00% | 10.15M | Aug 14, 20264 filings since Nov 14, 2025 | 13G/A | |
| BlackRock, Inc. | 6.30% | 8.48M | Jan 21, 20262 filings since Jul 17, 2025 | 13G | |
| The Goldman Sachs Groupwith 1 more person | 6.00% | 9.74M | Aug 14, 2026 | 13G |
What the holders on a 13D state as their purpose
From Item 4 of the filing, in the holder's own words. It is the intention the holder states, not something that happened.
BCTG Holdings, LLC10.0%From the filing of Jan 2, 2025
Item 4 is hereby amended by the addition of the following: The disclosure set forth above in Item 3 is hereby incorporated herein.
From the filing of Jan 2, 2025
Fell to 5% or less (7)
Holders whose latest filing says they hold 5% or less. After it they need not file again, so what they hold today is not known.
- Woodline Partners LP2.50%Aug 14, 202613G/A
- Nextech Crossover I GP S.a. r.l.0.00%Aug 14, 202613G/A
- Adage Capital Management, L.P.3.44%Aug 12, 202613G/A
- Invus Public Equities, L.P.4.00%May 4, 202613G/A
- The Vanguard Group0.00%Mar 27, 202613G/A
- EcoR1 Capital, LLC0.00%Feb 17, 202613G/A
- Third Rock Ventures IV, L.P.13D4.74%Feb 10, 202613D/A
From the Schedule 13D and 13G filed with the SEC since Dec 18, 2024, when they became structured data. A holder who has filed nothing since then is not shown here. A 13D is updated within two business days of any material change, a 13G up to 45 days after the quarter of the change, so the shares are those of the filing. The large managers also appear in the 13Fs.
Well-known managers
Which of the about 30 investment managers we track held the shares at the quarter end, and what they changed from the quarter before.
- Point72 (Cohen)In the quarter
- Citadel Advisors (Griffin)In the quarter+146%
- Millennium Mgmt (Englander)In the quarter-23%
- Renaissance TechnologiesIn the quarter-48%
- D.E. ShawIn the quarter
- AQR CapitalIn the quarter+40%
| Manager | Shares | In the quarter | Value | % of their portfolio |
|---|---|---|---|---|
| Point72 (Cohen) | – | – | 0.01% | |
| Citadel Advisors (Griffin) | 445.4K | +146% | $11M | 0.01% |
| Millennium Mgmt (Englander) | 381.4K | -23% | $9.5M | 0.01% |
| Renaissance Technologies | 389.9K | -48% | $9.7M | 0.01% |
| D.E. Shaw | 60.4K | $1.5M | 0.00% | |
| AQR Capital | 127.2K | +40% | $3.2M | 0.00% |
From the 13Fs managers file with the SEC up to 45 days after each quarter end. They show only long positions on that day, not short sales or what has changed since. No recent 13F: Pershing Square (Ackman), Scion (Burry).
Short interest
How many of the company's shares have been sold borrowed and not yet bought back, twice a month.
On Oct 15, 2026, 26.4% of its shares outstanding were held short, +0.6% since the report before.
- Shares held short
- 44.78M
- 26.4%
- Since the report before44.50M on Sep 30, 2026
- +0.6%
- 11.2
- 4.01M
- More days to cover thanof 4,578 US-listed companies with enough volume
- 94%
- Report date
- Oct 15, 2026
- Shares held short
- Oct 31, 2023: Shares held short 8.44M
- Nov 15, 2023: Shares held short 9.34M
- Nov 30, 2023: Shares held short 9.76M
- Dec 15, 2023: Shares held short 9.41M
- Dec 29, 2023: Shares held short 10.18M
- Jan 12, 2024: Shares held short 10.45M
- Jan 31, 2024: Shares held short 10.51M
- Feb 15, 2024: Shares held short 9.58M
- Feb 29, 2024: Shares held short 8.87M
- Mar 15, 2024: Shares held short 8.88M
- Mar 28, 2024: Shares held short 10.19M
- Apr 15, 2024: Shares held short 10.63M
- Apr 30, 2024: Shares held short 10.89M
- May 15, 2024: Shares held short 10.62M
- May 31, 2024: Shares held short 10.48M
- Jun 14, 2024: Shares held short 9.80M
- Jun 28, 2024: Shares held short 8.33M
- Jul 15, 2024: Shares held short 8.49M
- Jul 31, 2024: Shares held short 9.12M
- Aug 15, 2024: Shares held short 10.12M
- Aug 30, 2024: Shares held short 10.21M
- Sep 13, 2024: Shares held short 10.45M
- Sep 30, 2024: Shares held short 10.81M
- Oct 15, 2024: Shares held short 8.90M
- Oct 31, 2024: Shares held short 9.08M
- Nov 15, 2024: Shares held short 7.11M
- Nov 29, 2024: Shares held short 7.22M
- Dec 13, 2024: Shares held short 8.06M
- Dec 31, 2024: Shares held short 7.49M
- Jan 15, 2025: Shares held short 7.02M
- Jan 31, 2025: Shares held short 5.44M
- Feb 14, 2025: Shares held short 5.94M
- Feb 28, 2025: Shares held short 7.04M
- Mar 14, 2025: Shares held short 9.11M
- Mar 31, 2025: Shares held short 10.04M
- Apr 15, 2025: Shares held short 11.24M
- Apr 30, 2025: Shares held short 12.55M
- May 15, 2025: Shares held short 13.75M
- May 30, 2025: Shares held short 15.95M
- Jun 13, 2025: Shares held short 15.67M
- Jun 30, 2025: Shares held short 21.19M
- Jul 15, 2025: Shares held short 21.53M
- Jul 31, 2025: Shares held short 22.48M
- Aug 15, 2025: Shares held short 25.16M
- Aug 29, 2025: Shares held short 25.40M
- Sep 15, 2025: Shares held short 26.80M
- Sep 30, 2025: Shares held short 33.81M
- Oct 15, 2025: Shares held short 36.35M
- Oct 31, 2025: Shares held short 29.39M
- Nov 14, 2025: Shares held short 30.82M
- Nov 28, 2025: Shares held short 33.25M
- Dec 15, 2025: Shares held short 33.55M
- Dec 31, 2025: Shares held short 39.97M
- Jan 15, 2026: Shares held short 42.75M
- Jan 30, 2026: Shares held short 45.82M
- Feb 13, 2026: Shares held short 47.04M
- Feb 27, 2026: Shares held short 48.74M
- Mar 13, 2026: Shares held short 47.25M
- Mar 31, 2026: Shares held short 40.37M
- Apr 15, 2026: Shares held short 40.25M
- Apr 30, 2026: Shares held short 38.25M
- May 15, 2026: Shares held short 31.81M
- May 29, 2026: Shares held short 33.49M
- Jun 15, 2026: Shares held short 34.04M
- Jun 30, 2026: Shares held short 42.01M
- Jul 15, 2026: Shares held short 42.72M
- Jul 31, 2026: Shares held short 44.61M
- Aug 14, 2026: Shares held short 43.19M
- Aug 31, 2026: Shares held short 42.63M
- Sep 15, 2026: Shares held short 41.87M
- Sep 30, 2026: Shares held short 44.50M
- Oct 15, 2026: Shares held short 44.78M
As brokers report them to the regulator twice a month, mid-month and at month end, published about eight business days later. A short position is shares sold borrowed and not yet bought back. The share count is the one the company's market value is figured on, from its filings. Days to cover is the shares held short over the average daily volume of the weeks between two reports.
Short sales in daily trading51.2% of the shares in the last 14 sessions' reported trades were short sales.
In the last 14 sessions, 51.2% of the shares in the reported trades were short sales, against 57.2% in the 14 before.
- Last 14 sessionsNov 2, 2026 – Nov 19, 2026
- 51.2%
- The 14 beforeOct 13, 2026 – Oct 30, 2026
- 57.2%
- Change
- -6.0 pts
- Short sales a dayon average, of 1.14M shares
- 583.0K
- More than atof 3,666 US-listed companies, same days
- 53%
- Median of alleight in ten from 34.5% to 63.8%
- 50.4%
- Short sales
- Oct 13, 2026: Short sales 65.5%
- Oct 14, 2026: Short sales 78.1%
- Oct 15, 2026: Short sales 70.3%
- Oct 16, 2026: Short sales 52.9%
- Oct 19, 2026: Short sales 48.8%
- Oct 20, 2026: Short sales 49.5%
- Oct 21, 2026: Short sales 51.1%
- Oct 22, 2026: Short sales 66.9%
- Oct 23, 2026: Short sales 58.2%
- Oct 26, 2026: Short sales 50.1%
- Oct 27, 2026: Short sales 67.9%
- Oct 28, 2026: Short sales 55.5%
- Oct 29, 2026: Short sales 49.6%
- Oct 30, 2026: Short sales 35.1%
- Nov 2, 2026: Short sales 45.4%
- Nov 3, 2026: Short sales 37.6%
- Nov 4, 2026: Short sales 44.1%
- Nov 5, 2026: Short sales 60.7%
- Nov 6, 2026: Short sales 59.7%
- Nov 9, 2026: Short sales 41.7%
- Nov 10, 2026: Short sales 44.2%
- Nov 11, 2026: Short sales 35.7%
- Nov 12, 2026: Short sales 60.9%
- Nov 13, 2026: Short sales 60.7%
- Nov 16, 2026: Short sales 70.5%
- Nov 17, 2026: Short sales 68.5%
- Nov 18, 2026: Short sales 56.7%
- Nov 19, 2026: Short sales 55.1%
This is not the number of shares sold short today: it measures short sales within each day's trading, and only trades made off the exchanges. Much of it is market makers, who sell shares they do not have to fill buyers' orders and cover soon after, so for a heavily traded stock the share is often around half.
What the insiders hold
The shares each insider reports holding after their latest trade (Form 4), for those who traded on the market in the last three years.
- Third Rock Ventures IV, L.P.TenPercentOwnerDirectly17.00M
- Third Rock Ventures GP IV, L.P.TenPercentOwnerDirectly15.46M
- Trv Gp Iv, LlcTenPercentOwnerDirectly13.39M
- EcoR1 Capital, LLCTenPercentOwnerDirectly–
- Boxer Capital Management, LLCOtherDirectly6.69M
- Barbara WeberDirector, Executive ChairDirectly1.63M
- MVA Investors, LLCOtherDirectly108.8K
- Daniella BeckmanChief Financial OfficerDirectly184.3K
- Adam CrystalPresident, R&DDirectly115.7K
- Douglas BarryGeneral CounselDirectly66.0K
- Jessica NewcombPrincipal Accounting OfficerDirectly52.1K
- Mace RothenbergDirectorDirectly41.5K
- Sung LeeDirectorDirectly22.9K
- John B KetchumDirectorDirectly21.6K
- Lesley Ann CalhounDirectorDirectly16.5K
- Robert AzelbyDirectorDirectly5,740
| Person | Directly | Indirectly | After the trade of | Filing |
|---|---|---|---|---|
| Third Rock Ventures IV, L.P.TenPercentOwner | 17.00M | – | Aug 30, 2024 | Form 4 |
| Third Rock Ventures GP IV, L.P.TenPercentOwner | 15.46M | – | Aug 22, 2025 | Form 4 |
| Trv Gp Iv, LlcTenPercentOwner | 13.39M | – | Oct 23, 2025 | Form 4 |
| EcoR1 Capital, LLCTenPercentOwner | – | 10.63M | Nov 7, 2024 | Form 4 |
| Boxer Capital Management, LLCOther | 6.69M | 3.61M | Nov 6, 2024 | Form 4 |
| Barbara WeberDirector, Executive Chair | 1.63M | – | Feb 3, 2026 | Form 4 |
| MVA Investors, LLCOther | 108.8K | 483.5K | Jul 2, 2024 | Form 4 |
| Daniella BeckmanChief Financial Officer | 184.3K | – | Feb 3, 2026 | Form 4 |
| Adam CrystalPresident, R&D | 115.7K | – | Nov 11, 2026 | Form 4 |
| Douglas BarryGeneral Counsel | 66.0K | – | Feb 5, 2025 | Form 4 |
| Jessica NewcombPrincipal Accounting Officer | 52.1K | – | Nov 2, 2026 | Form 4 |
| Mace RothenbergDirector | 41.5K | – | Jun 5, 2026 | Form 4 |
| Sung LeeDirector | 22.9K | – | Jun 5, 2026 | Form 4 |
| John B KetchumDirector | 21.6K | – | Nov 17, 2026 | Form 4 |
| Lesley Ann CalhounDirector | 16.5K | – | Jun 5, 2026 | Form 4 |
| Robert AzelbyDirector | 5,740 | – | Jun 19, 2026 | Form 4 |
A lower bound: it counts only the 16 officers and directors with a market trade since Nov 21, 2023. Anyone who neither bought nor sold since is not here, whatever they hold. The share is against the share count on the latest 10-K's cover.
The ETFs that hold it
Which of the 345 US equity ETFs we track hold the stock, and at what weight, from the funds' N-PORT filings.
- XBIState Street(R) SPDR(R) S&P(R) Biotech ETFWeight in the fund0.84%
- LABUDirexion Daily S&P Biotech Bull 3X SharesWeight in the fund0.54%
- IBBiShares Biotechnology ETFWeight in the fund0.26%
- IWOiShares Russell 2000 Growth ETFWeight in the fund0.25%
- IWMiShares Russell 2000 ETFWeight in the fund0.14%
- VTWOVanguard Russell 2000 Index FundWeight in the fund0.10%
- SCHASchwab U.S. Small-Cap ETFWeight in the fund0.06%
- FESMFidelity Enhanced Small Cap Core ETFWeight in the fund0.05%
- VXFVanguard Extended Market Index FundWeight in the fund0.04%
- VHTVanguard Health Care Index FundWeight in the fund0.03%
17 of the 345 ETFs we track, not of every ETF on the market. The ten largest weights. Positions as each fund filed them in its latest N-PORT.
Institutional investors by quarter
Every manager that reports positions to the SEC (Form 13F), quarter by quarter: how many hold the stock, how many shares and dollars between them, and who entered, left, added or trimmed during the quarter.
- Managers
- Q3 2025: Managers 142
- Q4 2025: Managers 170
- Q1 2026: Managers 195
- Q2 2026: Managers 247
Institutional investors by quarter
The fund managers holding TNGX, quarter by quarter, from Q3 2021 to Q2 2025, 16 more quarters
Part of Ploutos Investor, €9.99 a month
Sign in with a free account to see the last 12 quarters.
Q2 2026: 247 managers held 215M shares, worth $6.6B. During the quarter 78 opened a position, 26 closed one, 97 added and 55 trimmed.
The largest holders, Q2 2026
- Rtw InvestmentsIn the quarter+4.5%
- BlackRockIn the quarter+42%
- FMRIn the quarter+25%
- Farallon Capital ManagementIn the quarter+35%
- Boxer Capital ManagementIn the quarter
- Goldman Sachs GroupIn the quarter+97%
- TCG Crossover ManagementIn the quarter-14%
- Trv Gp IvIn the quarter
- Paradigm Biocapital AdvisorsIn the quarter+59%
- Price T Rowe AssociatesIn the quarter+614%
| Manager | Shares | In the quarter | Value |
|---|---|---|---|
| Rtw Investments | 13.90M | +4.5% | $435M |
| BlackRock | 12.44M | +42% | $389M |
| FMR | 12.33M | +25% | $386M |
| Farallon Capital Management | 12.28M | +35% | $384M |
| Boxer Capital Management | 10.88M | $340M | |
| Goldman Sachs Group | 9.98M | +97% | $312M |
| TCG Crossover Management | 9.08M | -14% | $284M |
| Trv Gp Iv | 6.37M | $120M | |
| Paradigm Biocapital Advisors | 6.36M | +59% | $199M |
| Price T Rowe Associates | 6.35M | +614% | $198M |
From the SEC's Form 13F data sets, Q3 2025 to Q2 2026: the long positions of every manager with more than $100 million under management, as filed up to 45 days after each quarter end. Short positions and options are not in them. Shares as reported each quarter, not adjusted for splits. The stock is matched by its CUSIP, through the SEC's fails-to-deliver files.
Pay against performance, the say-on-pay vote, buybacks by quarter and trading plans are read for S&P 500 companies only.
The full analysis
What do Tango Therapeutics's filings show?
Who buys and sells is one part of Tango Therapeutics's picture. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.
- A fair value range built from the filings
- Earnings quality, debt and red flags
- Insider and institutional moves
- The case for and the case against
Have TNGX's insiders bought or sold?
From Jun 3, 2026 to Nov 19, 2026 Tango Therapeutics's insiders bought 0 and sold $4.1M of shares on the market. 100% of the sales were under set 10b5-1 plans.
Which well-known managers hold TNGX?
6 of the managers we track held the shares on Sep 30, 2026. The largest position was Citadel Advisors (Griffin)'s, worth $11M.
Is every insider transaction a purchase or a sale?
No. Many are part of their pay: share awards, option exercises and shares the company keeps for the tax. Only code P is a purchase with their own money, and code S a sale on the market.
Related pages
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.